Idexx Laboratories (IDXX): financials, SEC filings and peers

Idexx Laboratories (IDXX) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in Westbrook, Maine.

It was founded in 1983 and joined the S&P 500 on January 5, 2017.

Its fiscal year ends in December, and its shares trade on the Nasdaq.

In its SEC filings it is classified as “In Vitro & In Vivo Diagnostic Substances”.

Idexx Laboratories at a glance

Revenue (12 months): $4.6B
Revenue growth: +12.8%
Operating margin: 32.0%
Net income (12 months): $1.1B
Free cash flow (12 months): $1.3B
Cash: $197M
Debt: $450M
Diluted EPS (12 months): $14.23

Twelve months to June 30, 2026, from the 10-Q filed August 4, 2026.

Latest twelve months

Over the twelve months to June 30, 2026, Idexx Laboratories reported revenue of $4.6 billion, up 12.8% from a year earlier.

Its operating margin was 32.0%: for every $100 of sales, about $32 was left as operating profit.

Net income was $1.1 billion (25.0% of revenue), 15.6% higher than a year earlier.

Operating cash flow was $1.4 billion and capital spending $117 million, leaving free cash flow of $1.3 billion (27.5% of revenue).

At the end of the period it held $197 million in cash and $450 million in debt, a net debt position of $253 million.

The diluted share count fell 2.1% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $2.7 billion in fiscal 2020 to $4.3 billion in fiscal 2025, about 9.7% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin widened from 25.7% to 31.6% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$3.2B	$3.4B	$3.7B	$3.9B	$4.3B
Revenue growth	18.8%	4.7%	8.7%	6.5%	10.4%
Operating margin	29.0%	26.7%	30.0%	29.0%	31.6%
Net income	$745M	$679M	$845M	$888M	$1.1B
Free cash flow	$636M	$394M	$773M	$808M	$1.1B
Diluted EPS	$8.60	$8.03	$10.06	$10.67	$13.08

Fiscal years as reported in Idexx Laboratories’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed August 4, 2026 — quarterly report
8-K filed August 4, 2026 — Earnings results
8-K filed May 15, 2026 — Bylaw or fiscal-year change; Shareholder vote results
10-Q filed May 5, 2026 — quarterly report
8-K filed May 5, 2026 — Earnings results
8-K filed March 26, 2026 — Executive or director change
10-K filed February 20, 2026 — annual report
8-K filed February 13, 2026 — Executive or director change

All Idexx Laboratories filings on SEC EDGAR

Companies like Idexx Laboratories

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Idexx Laboratories

Is Idexx Laboratories's revenue growing?

Yes. Revenue for the twelve months to June 30, 2026 was $4.6 billion, up 12.8% from a year earlier, according to its SEC filings.

Is Idexx Laboratories profitable?

Yes. It earned $1.1 billion in net income over the twelve months to June 30, 2026, a net margin of 25.0%.

Does Idexx Laboratories have more cash or more debt?

At June 30, 2026 it had $197 million in cash and $450 million in debt, so more debt than cash.

When did Idexx Laboratories last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on August 4, 2026.

Which companies are similar to Idexx Laboratories?

In the S&P 500, Idexx Laboratories is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.

Understand the numbers

Source: Idexx Laboratories’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.